CARsgen Therapeutics Secures Victory as GPC3 CAR-T Patent Upheld by European Patent Office
Shanghai, China – July 14, 2025 – CARsgen Therapeutics Holdings Limited (HKEX: 2171, SSE STAR: 688276), a leading clinical-stage biopharmaceutical company focused on the development of innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced today a significant achievement in its intellectual property portfolio. The company has successfully defended its key patent relating to its GPC3 targeted CAR T-cell therapy at the European Patent Office (EPO). This decision by the EPO serves as a strong validation of CARsgen’s pioneering work in this promising area of cancer treatment.
The patent in question protects CARsgen’s novel CAR T-cell technology specifically designed to target Glypican-3 (GPC3), a protein that is highly expressed in several types of cancer, most notably hepatocellular carcinoma (HCC), also known as liver cancer. HCC is a significant global health challenge, and CAR T-cell therapy represents a potentially transformative approach to treating patients who have limited treatment options.
The legal challenge at the EPO involved scrutiny of the patent’s validity. Following a thorough examination and comprehensive presentation of evidence, the EPO has ruled in favor of CARsgen, upholding the patent. This outcome is a testament to the strength and inventiveness of CARsgen’s scientific research and development efforts.
“We are delighted with the EPO’s decision to uphold our GPC3 CAR-T patent,” said Dr. Zonghai Li, Founder, Chairman of the Board and Chief Executive Officer of CARsgen Therapeutics. “This ruling is a crucial milestone for CARsgen and underscores the originality and scientific merit of our proprietary CAR T-cell platform. It reinforces our commitment to advancing innovative therapies that can make a meaningful difference in the lives of patients with challenging diseases like liver cancer. This successful defense strengthens our position as we continue to progress our GPC3-targeted CAR T-cell therapy through clinical development.”
CARsgen’s GPC3-targeted CAR T-cell therapy, known as CT041, has shown promising preclinical and clinical results. The company is actively conducting clinical trials to evaluate the safety and efficacy of CT041 in patients with GPC3-positive solid tumors, with a particular focus on advanced HCC. The successful defense of this patent is expected to provide further clarity and security for the company as it navigates the regulatory and commercial landscape for its innovative treatments.
This positive outcome at the EPO not only safeguards CARsgen’s intellectual property but also demonstrates the company’s dedication to scientific rigor and its ability to protect its valuable innovations. CARsgen remains focused on bringing its groundbreaking therapies to patients in need, and this patent victory is a significant step forward in achieving that mission. The company looks forward to continuing to advance its pipeline and deliver hope to cancer patients worldwide.
CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO
AI has delivered the news.
The answer to the following question is obtained from Google Gemini.
www.prnewswire.com published ‘CARsgen Successfully Defends Its GPC3 CAR-T Patent at the EPO’ at 2025-07-14 00:00. Please write a detailed article about this news in a polite tone with relevant information. Please reply in English with the article only.